AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06563856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEPEZZA
Description: Administered as a SubQ injection or IV injection.
Study NCT03839017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAXMARCHERYAN2
Description: Digital cognitive aid during the management of simulated war wounded.
Study NCT01000779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: upto 320mg/day maximum
Study NCT01000779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multi band ligator for esophageal varices
Description: to obliterate esophageal varices
Study NCT00748085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoSpray Ablation
Description: Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
Study NCT00245414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: 180μg for s.c./week for 48 weeks
Study NCT02514278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1600 mg/m2 daily 5 days/7
Study NCT02514278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1600 mg/m2 daily 5 days/7
Study NCT01480505 — intervention group
Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy with gas tamponade
Description: A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment.
Study NCT00245414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: 180μg for s.c./week for 24 weeks
Study NCT05194046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered
Study NCT06563856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP
Description: Administered as a SubQ injection.
Study NCT03405740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Management
Description: 1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access
Study NCT04205968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04205968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04205968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study NCT03525171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: euglycemic hyperinsulinemic clamp
Description: In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
Study NCT03525171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: euglycemic hyperinsulinemic clamp
Description: In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
Study NCT01550731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE website
Description: Advance care planning website and materials plus an advance directive.
Study NCT01550731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance directive
Description: The control group will only receive an advance directive.
Study NCT05581862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 meals+3 snacks
Description: All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
Study NCT05581862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 meals
Description: All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
Study NCT02438020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One tablet of 500 mg will be ingested before the main meal
Study NCT05652244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-implants
Description: En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
Study NCT02438020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet will be ingested daily before main meal.
Study NCT03461913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Lower segment elective Cesarean section
Study NCT05652244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transpalatal arche (TPA)
Description: Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
Study NCT02990546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midodrine
Description: Midodrine will be given to treatment arm as enteral medication
Study NCT02990546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients in the control arm will receive standard of care for septic shock
Study NCT02747381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: 1-alpha hydroxy cholecalciferol 1 mcg
Study NCT01760564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
Study NCT01683149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will be given by mouth as outlined in treatment arm.
Study NCT01683149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given by mouth as outlined in treatment arm.
Study NCT03899324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide white, oblong, scored tablet
Description: Bumetanide with a titration period
Study NCT03899324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo white, oblong, scored tablet
Description: placebo intake identically to group 1
Study NCT01353001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
Study NCT01353001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Plus Aerobic Training
Description: Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
Study NCT01353001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus Resistance Training
Description: Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
Study NCT05194046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500Mg Cap
Description: Amoxicilin 500Mg 2 capsules will be orally administered
Study NCT00854373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravelle(follicle stimulating hormone)
Description: One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
Study NCT00854373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline ( placebo)
Description: 1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
Study NCT00453817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferucarbotran (iron-based MRI contrast agent)
Description: islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
Study NCT00453817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Description: intraportal percutaneous islet transplantation
Study NCT05194046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Tab
Description: Amoxicilin 500Mg 1 tablet will be orally administered
Study NCT02853006 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and respiratory fluids sampling
Description: In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
Study NCT03405740 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: No intervention
Study NCT00453817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
Study NCT00878696 — intervention group
Intervention type: PROCEDURE
Intervention: TMS transcranial magnetic stimulation
Description: 200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz.
Study NCT00613834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
Study NCT00613834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: 5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
Study NCT04031612 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant therapy
Description: Neoadjuvant therapy
Study NCT03432234 — intervention group
Intervention type: OTHER
Intervention: Biomarkers
Description: This is an observational study, there is no intervention
Study NCT04523402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy with GEMOX regimen before liver resection
Study NCT03696355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: Given PO
Study NCT03696355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Both photon and proton therapy modalities will be allowed.
Study NCT04216615 — intervention group
Intervention type: BEHAVIORAL
Intervention: preoperative anxiety
Description: patients who are anxious
Study NCT00971984 — intervention group
Intervention type: OTHER
Intervention: Medical records summary
Description: Summary of Medical files and laboratory results.
Study NCT02919241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic interview
Description: A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
Study NCT02919241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined interview and treatment.
Description: Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
Study NCT02276898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline 7%
Description: PARI Hyper-Sal™ Sodium Chloride Solution - 7%
Study NCT02276898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline 0.9% (Placebo)
Study NCT00793741 — intervention group
Intervention type: DRUG
Intervention: somatostatin
Description: Somatostatin may be used to suppress endogenous insulin secretion
Study NCT01352728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
Study NCT02035020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma interferon
Description: IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Study NCT02446834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive lifestyle intervention
Description: 3 months low GI diet and exercise
Study NCT02446834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 Receptor Agonists
Description: Use GLP-1 Receptor Agonists 3 months to treat PCOS
Study NCT02446834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use metformin 3 months to treat PCOS
Study NCT02446834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Use acarbose 3 months to treat PCOS
Study NCT04108273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training
Description: OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
Study NCT04108273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Organizational Skills Training
Description: OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
Study NCT03248323 — intervention group
Intervention type: RADIATION
Intervention: dyna-pbv
Study NCT06325787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroid lobectomy
Description: thyroid lobectomy
Study NCT06325787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: image-guided thermal ablation
Description: radiofrequency ablation or microwave ablation or laser ablation
Study NCT01502735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DENV-1 PIV, 2.5 µg
Description: 2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
Study NCT00697606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seprafilm®
Description: Seprafilm® placed at time of primary cesarean
Study NCT00697606 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: no Seprafilm® used at primary cesarean
Study NCT03202901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-turmactive
Description: The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable
Study NCT02853006 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Study NCT02853006 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excised tissues
Study NCT01086150 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
Study NCT03202901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable
Study NCT01086150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 5% patches
Description: Subject will apply patches to affected area QD for 12 hours then remove.
Study NCT00049842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 0.5 µg/kg Weekly QW SC for 36 months
Study NCT03353402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
Study NCT03236948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women for Women International Intervention
Study NCT00952276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
Description: 0.5 mL, Intramuscular on Day 0
Study NCT00952276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Subvirion A/H1N1 influenza vaccine
Description: 0.5 mL, Intramuscular on Day 0
Study NCT02273778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Scan
Study NCT02273778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET-CT Scan
Study NCT02273778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT02021331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement without provisionalization
Study NCT02021331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with immediate provisionalization
Study NCT00424983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Study NCT00952276 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: 0.5 mL, Intramuscular on Day 0